1. An alternative antidiabetic medicinal product should be used in patients in whom an antidiabetic treatment is indicated

2. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment Nat Commun

3. BACKGROUND: We aimed to identify predictors of Anamnestic hypoglycaemia in type-2 diabetic patients on oral mono- or dual oral combination antidiabetic pharmacotherapy

4. An in vitro antidiabetic activity on α -amylase and α –glucosidase activity of novel 10-chloro-4-(2-chlorophenyl)-12-phenyl-5,6-dihydropyrimido[4,5- a ]Acridin-2-amines ( 3a – 3f ) were evaluated

5. In particular, several core ingredients from Huang-Lian, berberine Bisulfate, columbamine, coptisine, epiberberine, jatrorrhizine, oxyberberine, dehydrocheilanthifoline, and berberine were reported to have hypoglycemic and antidiabetic actions through the regulation of glucose metabolic effects and reduction of oxidative stress injury [5159].

6. phenylbutazone, azapropazon and oxyfenbutazone insulin and oral antidiabetic products metformin salicylates and p-amino-salicylic acid anabolic steroids and male sex hormones chloramphenicol coumarin anticoagulants fenfluramine fibrates ACE inhibitors fluoxetine allopurinol sympatholytics cyclo-, tro-and iphosphamides sulphinpyrazone certain long-acting sulphonamides tetracyclines MAO-inhibitors quinolone antibiotics probenecid miconazol pentoxyfylline (high dose parenteral) tritoqualine fluconazole